Iron, Inflammation, and a Deadly Paradox: Rethinking Cancer Wasting Through Ferroptosis

Cancer cachexia, the devastating wasting syndrome that strips patients of muscle and fat and shortens survival in advanced malignancy, has long resisted treatment because clinicians have treated it as a form of starvation. A new review published in iScience argues that this framing is fundamentally incomplete. Yan Li, Rui Chen, and Shengguang Ding propose that ferroptosis, an iron-dependent form of regulated cell death driven by the runaway oxidation of membrane lipids, offers a coherent framework for understanding how tumors and the immune system actively injure host metabolic tissues. Crucially, the review also identifies a therapeutic paradox: the very cell-death program that oncologists increasingly want to trigger inside tumors may be the same program accelerating the destruction of skeletal muscle and adipose tissue in the same patient.

Ferroptosis has become one of the most intensively studied topics in cancer biology over the past decade. The process begins when polyunsaturated fatty acids are activated by the enzyme ACSL4 and incorporated into phosphatidylethanolamine membrane lipids by LPCAT3. These peroxidizable substrates can then be oxidized by lipoxygenases or by iron-catalyzed Fenton chemistry, generating phospholipid hydroperoxides. When the burden of these lipid peroxides exceeds the cell’s repair capacity, membrane integrity collapses and the cell dies. The principal defense is the system xc⁻–glutathione–GPX4 axis, which imports cystine, builds glutathione, and enzymatically detoxifies lipid hydroperoxides. Parallel, GPX4-independent systems, including FSP1-CoQ10 at the plasma membrane, DHODH-CoQH2 in mitochondria, the GCH1-BH4 radical-trapping pathway, and the 7-dehydrocholesterol–DHCR7 sterol axis, provide compartment-specific buffering. All of these nodes are pharmacologically accessible, which is precisely why the authors find ferroptosis so attractive as a therapeutic framework.

What makes the framework relevant to cachexia is that the biochemical requirements of ferroptosis, redox-active iron, PUFA-rich membranes, and depleted antioxidant reserves, are exactly the conditions found in wasting tissues. Cachectic muscle and fat undergo profound lipid remodeling: adipose tissue ramps up lipolysis and browning, flooding the circulation with fatty acids, while muscle mitochondria leak reactive oxygen species. Inflammation simultaneously redistributes iron through the IL-6–hepcidin–ferroportin axis, producing systemic hypoferremia and anemia of inflammation. Yet the review highlights a critical nuance: low circulating iron can coexist with dangerous iron accumulation inside muscle fibers and adipocytes. Local iron importers such as DMT1/SLC11A2 and the ferritinophagy receptor NCOA4 can expand the labile iron pool within specific tissues even when the blood appears iron-depleted, lowering the threshold for ferroptotic injury in exactly the compartments that cachexia destroys.

The strongest causal evidence comes from two cancer-specific mechanisms. In lung cancer cachexia, neutrophils infiltrating adipose tissue and skeletal muscle release lipocalin-2, or LCN2, an iron-binding protein that drives iron-dependent lipid peroxidation in both tissue types. Preclinical models show that blocking LCN2, depleting neutrophils, chelating iron with deferoxamine, or inhibiting ferroptosis with liproxstatin-1 all attenuate wasting and improve survival. In pancreatic cancer, a separate study demonstrated that tumor-derived exosomal microRNA miR-203a-3p travels to skeletal muscle and induces ferroptosis through a ZEB1-linked program that upregulates the DMT1/SLC11A2 iron importer. Blocking ferroptosis in that model preserved muscle mass despite an ongoing tumor burden. Together, these findings reposition ferroptosis from a tumor-intrinsic death mechanism to a genuine tumor-host interface in which malignant and immune signals converge on iron handling within myofibers and adipocytes.

The authors are careful, however, to separate causal mechanisms from associative signatures. Many cachexia studies have inferred ferroptosis from elevated iron, malondialdehyde, 4-hydroxynonenal, lipid ROS, or altered ACSL4 and GPX4 expression. These markers are informative but not specific: inflammation, malnutrition, mitochondrial dysfunction, and chemotherapy toxicity can all produce lipid damage without canonical ferroptotic cell death. The review therefore ranks evidence by causal strength, reserving the strongest interpretation for studies with functional rescue through ferroptosis inhibitors, iron chelation, or genetic perturbation. By that standard, the LCN2 and miR-203a-3p axes qualify as direct mechanisms, while findings from sarcopenia, sepsis, and disuse models support biological plausibility but require cachexia-specific validation. The authors also emphasize that ferroptosis may operate as a continuum, from sublethal lipid peroxidation that impairs contractility and mitochondrial energetics to outright regulated cell death, and that future studies must measure muscle function and regeneration alongside peroxidation markers.

The review extends the framework across the whole body. In adipose tissue, ferroptosis likely cooperates with rather than replaces canonical wasting programs: enhanced lipolysis increases fatty acid availability, browning raises mitochondrial ROS, and inflammatory cytokines weaken antioxidant buffering, together creating a permissive environment for lipid radical propagation. Injured adipocytes may then release oxidized lipid mediators and damage-associated molecular patterns such as HMGB1 and ATP, amplifying inflammation and stimulating further muscle catabolism. In skeletal muscle, iron-driven oxidative stress can activate NF-κB and p38 MAPK signaling, inducing the atrophy genes atrogin-1 and MuRF1 and thereby linking lipid peroxidation directly to the ubiquitin-proteasome proteolytic machinery. Mitochondrial dysfunction, one of the most reproducible features of cachectic muscle, intersects reciprocally with ferroptosis through iron-sulfur cluster metabolism and heme turnover, though the authors caution against equating mitochondrial stress with ferroptosis itself.

Even the central nervous system enters the picture, though more tentatively. Anorexia is an early and clinically important component of cachexia, driven by inflammatory cytokines, hypothalamic and brainstem appetite circuits, melanocortin signaling, and endocrine mediators such as GDF15. Because neurons and glia are rich in polyunsaturated lipids and depend on tight iron and redox regulation, ferroptosis-relevant lipid peroxidation is biologically plausible in appetite-regulating regions. The review, however, is explicit that direct evidence linking overt hypothalamic ferroptotic cell death to cancer-associated anorexia remains limited. Until brain-region-specific lipidomics, iron imaging, and ferroptosis-rescue experiments are performed, central ferroptosis should be regarded as a potential modifier of anorexia rather than an established driver.

The most provocative section of the review confronts the therapeutic paradox head-on. Oncology increasingly seeks to induce ferroptosis in tumors, where it can kill therapy-resistant cells and cooperate with antitumor immunity, including CD8⁺ T cell-derived interferon-γ signaling. But cachectic host tissues share the same vulnerabilities: PUFA-rich membranes, inflammatory oxidative stress, iron redistribution, and limited antioxidant reserve. A striking preclinical study of a ketogenic diet combined with GPX4 inhibition illustrates the danger. The intervention successfully promoted tumor ferroptosis but simultaneously triggered rapid weight loss, muscle atrophy, and endocrine stress, shortening survival unless systemic adaptation was restored with dexamethasone. Inhibiting xCT/SLC7A11 or GPX4 raises mirror-image concerns, since these targets are host antioxidant defenses as well as tumor vulnerabilities. The authors therefore propose a split-ferroptosis paradigm: induce or sensitize ferroptosis in tumors when it improves oncologic response, while actively preserving ferroptosis resistance in skeletal muscle, adipose tissue, and neuroendocrine circuits.

Achieving that separation will demand disease-proximal targets, tissue-selective delivery, and careful scheduling. The review identifies LCN2 blockade and DMT1/SLC11A2 restriction as the most context-specific strategies, alongside radical-trapping antioxidants such as liproxstatin-1, reinforcement of glutathione and GPX4-dependent defenses, and modulation of GPX4-independent systems including FSP1-CoQ10 and GCH1-BH4. Nutritional interventions, including PUFA enrichment and ketogenic diets, should be treated as pharmacometabolic modulators rather than benign supportive care, because they can shift ferroptosis thresholds in both tumors and host tissues. The authors also propose a biomarker framework combining systemic iron-inflammation markers such as ferritin, hepcidin, and LCN2 with oxidized phosphatidylethanolamine lipidomics, defense-capacity readouts, and liquid biopsy of tumor-derived extracellular vesicle cargoes such as miR-203a-3p, all integrated with CT-derived body composition, grip strength, appetite, and survival. Recent biomarker-selected successes such as the GDF15-targeted drug ponsegromab demonstrate that mechanism-guided cachexia trials are feasible. If the split-ferroptosis framework holds up under longitudinal, tissue-resolved testing, it could move cachexia management beyond nonspecific nutritional support toward genuine mechanism-guided host protection, provided that clinicians never forget that the same cell-death program they are weaponizing against the tumor is one their patients’ muscles and fat cannot easily survive.

Subject of Research: The role of ferroptosis in cancer cachexia and the tumor-host therapeutic paradox

Article Title: Targeting host ferroptosis in cancer cachexia: Tumor-immune triggers, tissue wasting, and the therapeutic paradox

Article References: Li, Y., Chen, R., & Ding, S. (2026). Targeting host ferroptosis in cancer cachexia: Tumor-immune triggers, tissue wasting, and the therapeutic paradox. iScience, 29(11), Article 117764. https://doi.org/10.1016/j.isci.2026.117764

Image Credits: AI Generated

DOI: 10.1016/j.isci.2026.117764

Keywords: ferroptosis, cancer cachexia, skeletal muscle wasting, LCN2, GPX4, iron metabolism, lipid peroxidation, tumor microenvironment, miR-203a-3p, adipose tissue, inflammation, drug development